Why This Highflying Biotech Stock Zoomed Near A Profit-Taking ZoneInvestors Business Daily • 12/05/19
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on CTAD Investor Event (Transcript)Seeking Alpha • 12/05/19
Acadia Achieves Successful Late-Stage Study, But Narrow Beat Highlights One Big Potential Change Moving ForwardSeeking Alpha • 12/02/19
What Makes Acadia Pharmaceuticals (ACAD) a Strong Momentum Stock: Buy Now?Zacks Investment Research • 11/27/19
Acadia Pharmaceuticals Delivers Record Q3 Revenue, Fueled by Antipsychotic Drug NuplazidThe Motley Fool • 10/31/19
ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 10/31/19
Acadia Battles Back With Latest Nuplazid Data As Trial Is Stopped Early On Successful FindingSeeking Alpha • 09/13/19
'Pleasantly Surprised' Acadia Analysts See Blockbuster Potential For Pimavanserin In Dementia PsychosisBenzinga • 09/10/19